Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 12, 2011, Pages 1796-1803

  Farag, Sherif S ^a   Maharry, Kati ^b,c   Zhang, Mei Jie ^d   Pérez, Waleska S ^d   George, Stephen L ^c   Mrózek, Krzysztof ^b   DiPersio, John ^e   Bunjes, Donald W ^f   Marcucci, Guido ^b   Baer, Maria R ^g   Cairo, Mitchell ^h   Copelan, Edward ⁱ   Cutler, Corey S ^j   Isola, Luis ^k   Lazarus, Hillard M ^l   Litzow, Mark R ^m   Marks, David I ⁿ   Ringdén, Olle ^o   Rizzieri, David A ^c   Soiffer, Robert ^j   Larson, Richard A ^p   Tallman, Martin S ^q   Bloomfield, Clara D ^b   Weisdorf, Daniel J ^r   more..

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e BARNES JEWISH HOSPITAL   (United States)

^f UNIVERSITY HOSPITAL ULM   (Germany)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^h NewYork Presbyterian Hospital   (United States)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

^j DANA FARBER CANCER INSTITUTE   (United States)

^k MOUNT SINAI MEDICAL CENTER   (United States)

^l UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^m MAYO CLINIC ROCHESTER   (United States)

ⁿ BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^o KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^p UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^q MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^r UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

more..

Author keywords

Acute myeloid leukemia; Allogeneic; Chemotherapy; Reduced intensity

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PATIENT; COMPARATIVE STUDY; CYTOGENETICS; FEMALE; HIGH RISK POPULATION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; RECIPIENT; REDUCED INTENSITY CONDITIONING; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 80054717791     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.06.005     Document Type: Article

References (37)

1. Goldstone A.H., Burnett A.K., Wheatley K., et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98:1302-1311.
2. Schiffer C.A. Postremission therapy in older adults with acute myeloid leukemia: an opportunity for new drug development. Leukemia 2002, 16:745-747.
3. Rowe J.M., Neuberg D., Friedenberg W., et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004, 103:479-485.
4. Farag S.S., Archer K.J., Mrozek K., et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006, 108:63-73.
5. Burnett A.K., Milligan D., Goldstone A., et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high-risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol 2009, 145:318-332.
6. Cassileth P.A., Harrington D.P., Appelbaum F.R., et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998, 339:1649-1656.
7. Zittoun R.A., Mandelli F., Willemze R., et al. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995, 332:217-223.
8. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000, 96:4075-4083.
9. Yanada M., Matsuo K., Emi N., et al. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a meta-analysis. Cancer 2005, 103:1652-1658.
10. Koreth J., Schlenk R., Kopecky K.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301:2349-2361.
11. Alyea E.P., Kim H.T., Ho V., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005, 105:1810-1814.
12. Wong R., Giralt S.A., Martin T., et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003, 102:3052-3059.
13. Feinstein L.C., Sandmaier B.M., Hegenbart U., et al. Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. Br J Haematol 2003, 120:281-288.
14. Ringden O., Labopin M., Ehninger G., et al. Reduced-intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009, 27:4570-4577.
15. McClune B.L., Weisdorf D.J., Pedersen T.L., et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010, 28:1878-1887.
16. Popat U., Heslop H.E., Durett A., et al. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplant 2006, 37:547-552.
17. Flynn C.M., Hirsch B., Defor T., et al. Reduced-intensity compared with high-dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. Am J Hematol 2007, 82:867-872.
18. Estey E., de Lima M., Tibes R., et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007, 109:1395-1400.
19. Baer M.R., George S.L., Caligiuri M.A., et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: cancer and Leukemia Group B Study 9720. J Clin Oncol 2008, 26:4934-4939.
20. Marcucci G., Moser B., Blum W., et al. A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old. J Clin Oncol 2007, 25:7012. [abstract].
21. Dohner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
22. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
23. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
24. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
25. Shimoni A., Hardan I., Shem-Tov N., et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006, 20:322-328.
26. Huisman C., Meijer E., Petersen E.J., et al. Hematopoietic stem cell transplantation after reduced-intensity conditioning in acute myelogenous leukemia patients older than 40 years. Biol Blood Marrow Transplant 2008, 14:181-186.
27. Bertz H., Potthoff K., Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 2003, 21:1480-1484.
28. Mohty M., de Lavallade H., Ladaique P., et al. The role of reduced-intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no-donor comparison. Leukemia 2005, 19:916-920.
29. Herr A.L., Labopin M., Blaise D., et al. HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. Leukemia 2007, 21:129-135.
30. Remberger M., Mattsson J., Svahn B.M., et al. Using reduced-intensity conditioning and HLA-identical sibling donors, antithymocyte globulin increases the risk of relapse, which can be overcome by a high stem cell dose. Bone Marrow Transplant 2008, 42:769-771.
31. Cutler C., Kim H.T., Hochberg E., et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004, 10:328-336.
32. Cutler C., Li S., Ho V.T., et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007, 109:3108-3114.
33. Farag S.S., Wood L., Schwartz J., et al. Phase I trial of high-dose clofarabine and busulfan as a myeloablative regimen prior to allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory acute leukemia. Leukemia 2011, 25:599-60512.
34. Jabbour E., Giralt S., Kantarjian H., et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009, 115:1899-1905.
35. Lubbert M., Bertz H., Ruter B., et al. Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant 2009, 44:585-588.
36. Kolb H.J., Schmid C., Tischer J., et al. Allogeneic stem cell transplantation for MDS and sAML following reduced-intensity conditioning and preemptive donor lymphocyte transfusion [abstract]. Blood 2006, 108. abstract 324.
37. Rezvani K., Yong A.S., Mielke S., et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008, 111:236-242.